Obsessive-compulsive Disorder; Ocd
Description
Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002).Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999).
Clinical Features
Phenotypes and symptoms related to Obsessive-compulsive Disorder; Ocd
- Depressivity
- Anxiety
- Obsessive-compulsive behavior
- Tics
- Collectionism
- Skin-picking
Incidence and onset information
— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)— No data available about the known clinical features onset.
Researches and researchers
Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.Obsessive-compulsive Disorder; Ocd Recommended genes panels
| Panel Name, Specifity and genes Tested/covered |
|---|
 Serotonin Metabolism Deficiency NGS Panel.
By Fulgent Genetics Fulgent Genetics (United States).
SLC6A4, TPH1, AANAT, TPH2, HTR3C, HTR3E, DDC, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR5A, HTR6, HTR7
Specificity
12 %
Genes
100 % |
|
HTR2A.
By Fulgent Genetics Fulgent Genetics (United States).
HTR2A
Specificity
100 %
Genes
50 % |
|
HTR2A.
By Genelex (United States).
HTR2A
Specificity
100 %
Genes
50 % |
|
YouScript Psychotropic.
By Genelex (United States).
SLC6A4, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, HTR2A
Specificity
29 %
Genes
100 % |
|
GeneSight Psychotropic.
By Assurex Health, Inc. (United States).
SLC6A4, UGT1A4, UGT2B15, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HLA-A, HTR2A
Specificity
20 %
Genes
100 % |
|
Comprehensive Pharmacogenomics (PGX) Panel.
By ApolloGen, Inc. (United States).
SLCO1B1, VKORC1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, F5, HTR2A, MTHFR, OPRM1
Specificity
10 %
Genes
50 % |
|
OneOme RightMed comprehensive test.
By OneOme (United States).
SLCO1B1, SLC6A4, TPMT, UGT1A1, IFNL3, NUDT15, VKORC1, CYP2B6, CYP2C18, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, F2, F5, GRIK4 , (...)
View the complete list with 4 more genes
Specificity
9 %
Genes
100 % |
 Citalopram response.
By Xcode Life Xcode Life (India).
SLC6A4, CYP2C19, HTR2A
Specificity
67 %
Genes
100 % |
You can get up to 14 more panels with our dedicated tool
Learn moreSources and references
You can check the following sources for additional information.
MESH OMIM Rare Disease Symptoms CheckerIf you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like VERHEIJ SYNDROME; VRJS LANGUAGE DELAY AND ATTENTION DEFICIT-HYPERACTIVITY DISORDER/COGNITIVE IMPAIRMENT WITH OR WITHOUT CARDIAC ARRHYTHMIA; LADCI MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 1; MCCRP1 MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B; LGMD1B LETHAL ARTHROGRYPOSIS WITH ANTERIOR HORN CELL DISEASE; LAAHD EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE; EPM4 WAISMAN SYNDROME; WSMN